HUTCHMED (China) Limited (HCM)
14.98
1.26 (9.18%)
At close: Apr 14, 2025, 3:59 PM
14.94
-0.27%
After-hours: Apr 14, 2025, 07:56 PM EDT
9.18% (1D)
| Bid | 14.75 |
| Market Cap | 2.61B |
| Revenue (ttm) | 630.2M |
| Net Income (ttm) | 37.73M |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 74.9 |
| Forward PE | 90.27 |
| Analyst | Hold |
| Ask | 15.15 |
| Volume | 117,947 |
| Avg. Volume (20D) | 100,560 |
| Open | 14.41 |
| Previous Close | 13.72 |
| Day's Range | 14.21 - 15.09 |
| 52-Week Range | 11.51 - 21.92 |
| Beta | 0.72 |
About HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for ...
Sector Healthcare
IPO Date Mar 16, 2016
Employees 1,811
Stock Exchange NASDAQ
Ticker Symbol HCM
Website https://www.hutch-med.com
Analyst Forecast
According to 1 analyst ratings, the average rating for HCM stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 26.84% from the latest price.
Stock Forecasts3 weeks ago
+8.23%
HUTCHMED shares are trading higher. The company re...
Unlock content with
Pro Subscription
3 months ago
+4.65%
HUTCHMED shares are trading higher after the company announced the divestment of its 45% interest in Shanghai Hutchison Pharmaceuticals.
